bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Growth in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 816,644 shares, an increase of 124.8% from the June 15th total of 363,268 shares. Based on an average trading volume of 849,109 shares, the short-interest ratio is currently 1.0 days. Currently, 17.7% of the shares of the company are short sold.

bioAffinity Technologies Price Performance

Shares of BIAF stock traded down $0.01 during trading on Thursday, hitting $0.71. The company had a trading volume of 15,623 shares, compared to its average volume of 4,226,729. The firm has a market capitalization of $3.38 million, a P/E ratio of -0.06 and a beta of -1.11. bioAffinity Technologies has a one year low of $0.61 and a one year high of $13.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.34 and a current ratio of 1.36. The stock’s 50-day moving average price is $1.32 and its 200 day moving average price is $1.72.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Analyst Upgrades and Downgrades

BIAF has been the topic of a number of recent research reports. Weiss Ratings lowered bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Wall Street Zen downgraded bioAffinity Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, July 5th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On bioAffinity Technologies

Large investors have recently bought and sold shares of the company. Scientech Research LLC bought a new stake in shares of bioAffinity Technologies during the 3rd quarter worth approximately $49,000. Geode Capital Management LLC acquired a new position in bioAffinity Technologies during the fourth quarter valued at approximately $36,000. Finally, J. Safra Sarasin Holding AG acquired a new position in bioAffinity Technologies during the first quarter valued at approximately $164,000. 1.64% of the stock is currently owned by institutional investors and hedge funds.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.